Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-08
2009-08-25
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07579372
ABSTRACT:
Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, an alpha-ketoepoxide group, such as an alpha-ketothio group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or to stimulate hematopoietic cells ex vivo.
REFERENCES:
patent: 4447627 (1984-05-01), Näf et al.
patent: 5451689 (1995-09-01), Matsumoto et al.
patent: 5935773 (1999-08-01), Hagemann et al.
patent: 6147224 (2000-11-01), Vuligonda et al.
patent: 6201123 (2001-03-01), Daikai et al.
patent: 6262278 (2001-07-01), Jacobsen et al.
patent: 2-279735 (1990-11-01), None
patent: 9-249984 (1997-09-01), None
patent: 1063814 (1983-12-01), None
patent: WO 96/28402 (1996-09-01), None
patent: WO 97/35990 (1997-10-01), None
patent: WO 99/31063 (1999-06-01), None
patent: WO 02/34247 (2002-05-01), None
Hayakawa et al., “Asymmetric total synthesis of PM-toxin A, a corm host-specific pathotoxin,”Chemical Communications-Chemcon., vol. 13, p. 1219-20 (1997).
XP002470500, Database Accession No. 1985:437303, Pashaev et al., “Condensation of epoxy ketones with unsaturated aldehydes,”Azerbaidzhanskii Khimicheskii Zhurnal, (1984), (4), 70-2 (Abstract).
XP002470501, Database Accession No. 1978:615128, Pashaev et al., “Synthesis and study of conjugated dienic epoxy ketones,”Azerbaidzhanskii Khimicheskii Zhurnal, (1978), (2), 48-52 (Abstract).
Bohlmann et al., Phytochemistry, 21 (7), pp. 1679-1691, 1982.
Colletti et al., “Design and Synthesis of Histone Deacetylase Inhibitors: The Development of Apicidin Transition State Analogs,” Tetrahedron Letters, 41, 2000, 7837-7841.
Collins et al., “Oral Sodium Phenylbutyrate Therapy in Homozygous β Thalassemia: A Clinical Trial,” Blood, 85(1), 1995, 43-49.
Denney et al., “Preparation and Reactions of Some Phosphobetaines,” J. Org. Chem., 27, 1962, 3404-3408.
Dunn et al., “3-tert-Butyldimethylsilyoxymethyl-2-lithio-2-phenylsulfonyloxirane as a Glycidyl Anion Equivalent; Preparation of Terminal Epoxy Ketones,” J. Chem Soc. Perkin Trans. 1 (1992), (21), 2863-70.
Freuhauf et al., “Use of the Extreme Drug Resistance Assay to Evaluate Mechanisms of Resistance in Ovarian Cancer: Taxol Resistance and MDR-1 Expression,” Chemosensitivity Testing in Fyneologic Malignancies and Breast Cancer, 19, 1994, 39-52.
Grunstein, “Histoneactylation in chromatin structure and transcription,” Nature, 389, 1997, 349-352.
Hoffman et al., “A non-isotopic assay for histone deacetylase activity,” Nucleic Acids Research, 27(9), 1999, 2057-2058.
Kolle et al., “Biochemical Methods for Analysis of Histone Deacetylases,” Methods: A Comparison to Methods in Enzymology, 15, 1998, 323-331.
Moser et al., “Measurement of Saturated Very Long Chain Fatty Acids in Plasma,” Techniques in Diagnostic Human Biochemical Genetics: A Laboratory Manual, 1991, 177-191.
Panyim et al., “High Resolution Acrylamide Gel Electrophoresis of Histones,” Archives of Biochemistry and Biophysics, 130, 1969, 337-346.
Parameswara et al., “One-Step Vilsmeier Route to Some 5-Aryl-3-methyl-2(E), 4(E)-pentadienals and their Oxidation to Penta-dienoic Acids,” Syntheis, 1980, 815-818.
Pashaev et al., Azerb. Khim. Zh. (1978), (2) 48-52.
Pazin et al., “What's Up and Down with Histone Deacetylation and Transcription?,” Cell, 89, 1997, 325-328.
Steffan et al., “Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosphila,” Nature, 413, 2001, 739-743.
Steinberg, “The acetylation state of nuclear proteins could be one key to pathology and treatment,” The Scientist, 16 (2), 2002, 34.
Trager et al., “Human Malaria Parasites in Continuous Culture,” Science, 193, 1976, 673-675.
Wade et al., “Histone acetylation: chromatin in action,” Trends Biochem. Sci., 22, 1997, 128-132.
Watkins et al., “Peroxisomal Fatty Acid β-Oxidationin HepG2 Cells,” Archives of Biochemistry and Biophysics, 289 (2), 1991, 329-336.
Wolffe, “Histone Deacetylase: A Regulator of Transcription,” Science, 272, 1996, 371-372.
Kaufman Robert J.
Lan-Hargest Hsuan-Yin
Dentz Bernard
Errant Gene Therapeutics, LLC
Steptoe & Johnson LLP
LandOfFree
Histone deacetylase inhibitors based on alpha-ketoepoxide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Histone deacetylase inhibitors based on alpha-ketoepoxide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Histone deacetylase inhibitors based on alpha-ketoepoxide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4063292